central nervous system

Johnson & Johnson to Acquire Intra-Cellular Therapies

Johnson & Johnson and Intra-Cellular Therapies recently entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders.

News

Newron Licenses Evenamide to Myung In Pharm

Newron Pharmaceuticals, a central nervous system (CNS) focused biopharmaceutical company, and Myung In Pharm, South Korea’s leading CNS pharmaceutical company, today announced that they have entered into a license agreement to develop, manufacture, and commercialize Newron’s schizophrenia treatment evenamide.

News

Sanofi, Principia to Develop MS Candidate

Top-Feature

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

INOSIM GmbH

Predictive Simulation in Pharma Production

Aenova Holding GmbH

Aseptic processing by design: The flexible and efficient use of RABS and Isolators

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Johnson & Johnson

Myung in Pharm